Sept 2 (Reuters) - Two key U.S. congressional committee
members on Friday called for an investigation into whether Mylan
NV, under fire for raising the price of its EpiPen
device, overcharged the government's low-income healthcare
program for the allergy treatment.
Read more
No comments:
Post a Comment